KIMBERLY PURCELL-HOUCK: Open Payments
NPI 1740917129 · SALEM, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$437 in 25 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $245 · 2025 $437
Food & beverage: $437
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $72 |
| ABBVIE INC. | 4 | $71 |
| Lilly USA, LLC | 3 | $59 |
| GlaxoSmithKline, LLC. | 3 | $55 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $42 |
| AstraZeneca Pharmaceuticals LP | 2 | $37 |
| Novo Nordisk Inc | 2 | $36 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $16 |
| PFIZER INC. | 1 | $14 |
Products named: Kerendia, VRAYLAR, MOUNJARO, TRELEGY ELLIPTA, XIFAXAN, BREZTRI, REXULTI, Ozempic.
Industry payments across MO — which companies pay providers there.
